Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osengleiset
- Development stage
- Phase 2
- Lead developer
- Kunming Institute of Botany
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Osengleiset is a botanical drug candidate developed by the Kunming Institute of Botany, Chinese Academy of Sciences, for the treatment of major depressive disorder (MDD). Derived from the plant *Osbeckia nepalensis* Hook. (Nepal Osbeckia), it is a standardized extract formulated as an oral capsule. The drug is classified as a multi-target antidepressant, with preclinical evidence suggesting it acts by inhibiting the reuptake of monoamine neurotransmitters, specifically serotonin and norepinephrine, thereby increasing their synaptic concentrations. It has been evaluated in Phase II clinical trials in China for adult outpatients with mild to moderate MDD.
- Other names
- 奥生乐赛特Nepal Osbeckia extract
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on osengleiset.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osengleiset.